HS628 has been developed as a proposed biosimilar product of originator tocilizumab (Actemra). An extensive physicochemical\nand biological characterization was conducted to assess similarity between HS628 and originator tocilizumab. The amino\nacid sequence was shown to be identical between HS628 and originator tocilizumab. The higher order structure was found\nto be indistinguishable from originator tocilizumab. Concerning purity and heterogeneity, HS628 was demonstrated to have\nsimilar posttranslational modifications, charge heterogeneity, size heterogeneity, and glycosylation to originator tocilizumab.\nMoreover, HS628 exhibited highly similar binding affinity and antiproliferative activity as well as capability of inhibiting STAT3\nphosphorylation compared to originator tocilizumab. Taken together, HS628 can be considered as a highly similar molecule to\noriginator tocilizumab in terms of physicochemical and biological properties.
Loading....